Table 1.
Cellular target | Candidate site | Clinical efficacy | Status |
---|---|---|---|
Pyramidal cell | mGluR2/3 ( +) | high | Phase IIb clinical |
NR2B (−) | – | Early clinical | |
α2 GABAA (+) | – | Early clinical | |
α5 GABAA (+) | Preclinical | ||
Interneuron | D1 (+) | – | Early clinical |
Astrocyte | PAR1 (−) | – | Preclinical |
mGluR1/5 (−) | – | Preclinical |
Negative sign (−) antagonist, positive sign (+) agonist/positive modulator